About Quantum-Si
Quantum-Si is pioneering the post-genomic era by making protein sequencing accessible to researchers worldwide. Founded in 2013, the company has developed the world's first next-generation protein sequencing instruments—Platinum and Platinum Pro—which deliver single-molecule, single-amino acid resolution in compact benchtop systems. By integrating biology, chemistry, and artificial intelligence, Quantum-Si empowers researchers to study proteins at an unprecedented scale and detail. The company's proprietary technology uses kinetic signatures to sequence proteins directly at the single-molecule level, providing capabilities that simplify sequencing compared to Edman degradation, dive deeper than mass spectrometry with single-molecule resolution, and detect amino acid-level changes missed by immunoassays. This approach enables precise detection of proteoforms, post-translational modifications, protein variants, and isobaric variations without relying on antibodies or complex workflows. Quantum-Si's platforms support a streamlined workflow requiring less than three hours of hands-on time and work with nanogram protein inputs (200 ng or less). The technology serves diverse applications including biomarker discovery, disease mechanism research, drug development, antibody characterization, and protein barcoding for multiplexed variant screening. The company's innovation is driving groundbreaking advancements in scientific research, therapeutic development, and clinical proteomics, with recent peer-reviewed publications demonstrating value in clinical research and pathogen/toxin detection.
Mission & Story
Mission
Pioneering the post-genomic era by making protein sequencing accessible
Founding Story
Founded in 2013 to pioneer accessible protein sequencing technology
Who It Serves
Milestones & Awards
Recent Milestones
Expansion of Proteus Roadshow (June 2026). Partnership with Cell Signaling Technology for PTM analysis (June 2026). Publication of peer-reviewed paper in Analytical Chemistry from Stanford. Preprint publication from Naval Research Laboratory on pathogen detection.
Awards & Recognition
Next-Generation Protein Sequencing Technology Innovation Leadership 2023. Proteomics Company of the Year. Innovation by Design 2023.
Key Partnerships
Social & Media
Latest Updates
Grant for Broad Institute and Affiliated Researchers
Optimization of Quantum-Si Platinum single-molecule protein sequencing platform towards improved complex matrix protein identification
Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Exploration of semiconductor chip-based single-molecule protein sequencing for identification of hemoglobin variants
Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™
Company Details
- Founded
- 2013
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSimilar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.